MetaTrader
  • Markets
  • Charts & Ideas
  • Algo
  • News
  • Store
  • Brokers
  • Download
  • Economic Calendar
  • Trading Signals
  • WebTerminal
  • Русский Русский
  • 中文 中文
  • Español Español
  • Português Português
  • 日本語 日本語
  • Deutsch Deutsch
  • 한국어 한국어
  • Français Français
  • Italiano Italiano
  • Türkçe Türkçe
Celldex Therapeutics, Inc

CLDX

#3995
Celldex Therapeutics, Inc
30.0900
+0.40%
Sector:
Base:
Profit Currency:
Daily Range
30.0000
30.0900
Year Range
22.1000
31.2900
Daily Change
+0.40%
Monthly Change
+14.80%
6 month change
+10.46%
Year Change
+10.46%
Previous Close
29.9700
Open
30.0000
Bid
Ask
Low
30.0000
High
30.0900
Volume
102
  1. Markets
  2. US Stock Market
  3. Healthcare
  4. CLDX
Open full chart

Financials

Overview Statement Statistics Dividends
Quarterly Annual
Value Q3, 24Q4, 24Q1, 25Q2, 25Q3, 25Q4, 25 TTM

News

Investing Investing
CLDX
yesterday, 19:49
Celldex presents phase 2 data for chronic urticaria treatment
Investor's Business Daily Investor's Business Daily
CLDX INVA UTHR FOLD
2 days ago, 08:00
Celldex Therapeutics Stock Earns 88 RS Rating
Investing Investing
CLDX
2 days ago, 00:14
Celldex Therapeutics earnings missed by $0.21, revenue fell short of estimates
Investing Investing
CLDX
2026.02.25
Celldex Therapeutics stock hits 52-week high at 30.66 USD
Investing Investing
CLDX
2026.02.25
Stifel reiterates Celldex Therapeutics stock rating on trial progress
Investing Investing
CLDX
2026.02.25
Celldex completes Phase 3 enrollment for CSU treatment ahead of schedule
Investing Investing
CLDX
2026.01.06
Celldex stock rating reiterated as Overweight by Cantor Fitzgerald
Investor's Business Daily Investor's Business Daily
CLDX EXAS GMAB KRYS
2025.12.22
Celldex Therapeutics Stock Gets RS Rating Lift
Benzinga Benzinga
ARGX XCUR CLDX Z NOW
2025.12.15
Argenx, ServiceNow And Other Big Stocks Moving Lower In Monday's Pre-Market Session - argenx (NASDAQ:ARGX), Celldex Therapeutics (NASDAQ:CLDX)
Investing Investing
CLDX
2025.12.09
Celldex initiates phase 3 trial for cold urticaria and dermographism drug
Investing Investing
CLDX
2025.12.04
Celldex Therapeutics stock hits 52-week high at $29.14
Investing Investing
CLDX
2025.11.11
Stifel reiterates Buy rating on Celldex Therapeutics stock amid urticaria trials

Markets

  • US Stock Market
  • Currencies
  • Cryptocurrencies
  • Metals
  • Commodities

Charts & Ideas

  • Trading Ideas
  • Education Ideas
  • Charts

MQL5 Community

  • Market
  • Signals
  • Forum
  • Articles
  • CodeBase

News

  • US Stock Market
  • Currencies
  • Cryptocurrencies
  • Metals
  • Commodities

Brokers

  • All Brokers
  • Forex
  • Stock
  • Metals
MetaTrader 5
MQL5 Channels
Economic Calendar
Disclaimer and Risk Disclosure Terms of Use Contacts and Requests Legal
Copyright 2000-2026, MetaQuotes Ltd